Eighty-six patients with chronic symptomatic knee osteoarthritis were randomized to receive either high-dose cannabidiol (CBD; n=43) or placebo (n=43) as an add-on to continued paracetamol. The primary outcome of interest was the change in the Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) pain subscale over 8 weeks. Secondary outcomes included changes in WOMAC stiffness and physical function subscales, Visual Analogue Scale (VAS) pain scores, PainDETECT score, and SF-36 health survey scores. Outcomes were assessed at baseline, 4 weeks, 8 weeks, and follow-up at 12 weeks. Overall, the study revealed no significant difference in pain reduction between the CBD and placebo groups. The study concluded that high-dose oral CBD did not provide additional pain relief compared to placebo in KOA patients.